US FDA approves Elanco's skin disease treatment for dogs (updated)

Elanco Animal Health Incorporated

19/09/2024 18:04

(Adds details on drug in paragraphs 2, 3, 6 and 7, shares in
paragraph 4)
       Sept 19 (Reuters) - The U.S. Food and Drug
Administration has approved Elanco Animal Health's  ELAN.N  skin
disease treatment for dogs, the health regulator's website
showed on Thursday.
    The oral drug, Zenrelia, is to control pruritus, or itching,
associated with allergic dermatitis and control of atopic
dermatitis in dogs at least 12 months of age.
        Zenrelia, an immunosuppressant,is administered once
daily, with or without food.
  
        Shares of the company rose 3% in afternoon trade.
  
        The company did not immediately respond to Reuters'
request for pricing and availability.
  
        The label of the drug recommends it should have a 28-day
to 3-month washout period before any vaccination, and should not
be administered for at least 28 days afterwards.
  
        Zenrelia belongs to a class of drugs known as JAK
inhibitors, which block inflammation-causing enzymes known as
Janus kinases.
  

 (Reporting by Sriparna Roy in Bengaluru; Editing by Alan
Barona)
 ((Sriparna.Roy@thomsonreuters.com))